404 related articles for article (PubMed ID: 30173073)
21. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis.
Basu R; Bhaumik S; Basu JM; Naskar K; De T; Roy S
J Immunol; 2005 Jun; 174(11):7160-71. PubMed ID: 15905560
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
23. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge.
Marques-da-Silva EA; Coelho EA; Gomes DC; Vilela MC; Masioli CZ; Tavares CA; Fernandes AP; Afonso LC; Rezende SA
Parasitol Res; 2005 Dec; 98(1):67-74. PubMed ID: 16261353
[TBL] [Abstract][Full Text] [Related]
24. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
25. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.
Lehmann J; Enssle KH; Lehmann I; Emmendörfer A; Lohmann-Matthes ML
J Interferon Cytokine Res; 2000 Jan; 20(1):63-77. PubMed ID: 10670653
[TBL] [Abstract][Full Text] [Related]
26. Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice.
Goyal DK; Keshav P; Kaur S
Immunobiology; 2021 Mar; 226(2):152057. PubMed ID: 33545508
[TBL] [Abstract][Full Text] [Related]
27. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.
Kumari S; Samant M; Misra P; Khare P; Sisodia B; Shasany AK; Dube A
Vaccine; 2008 Oct; 26(45):5700-11. PubMed ID: 18762224
[TBL] [Abstract][Full Text] [Related]
28. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
Nagill R; Kaur S
Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
[TBL] [Abstract][Full Text] [Related]
29. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection.
Ahuja SS; Reddick RL; Sato N; Montalbo E; Kostecki V; Zhao W; Dolan MJ; Melby PC; Ahuja SK
J Immunol; 1999 Oct; 163(7):3890-7. PubMed ID: 10490989
[TBL] [Abstract][Full Text] [Related]
31. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.
Sukumaran B; Tewary P; Saxena S; Madhubala R
Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811
[TBL] [Abstract][Full Text] [Related]
32. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
[TBL] [Abstract][Full Text] [Related]
33. Immunological characterization of rLdTCP1γ for its prophylactic potential against visceral leishmaniasis in hamster model.
Anand A; Balodi DC; Ramalingam K; Yadav S; Goyal N
Mol Immunol; 2022 Jan; 141():33-42. PubMed ID: 34798496
[TBL] [Abstract][Full Text] [Related]
34. Modulation of CD11C+ splenic dendritic cell functions in murine visceral leishmaniasis: correlation with parasite replication in the spleen.
Basu A; Chakrabarti G; Saha A; Bandyopadhyay S
Immunology; 2000 Feb; 99(2):305-13. PubMed ID: 10692051
[TBL] [Abstract][Full Text] [Related]
35. Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis.
Martins VT; Chávez-Fumagalli MA; Lage DP; Duarte MC; Garde E; Costa LE; da Silva VG; Oliveira JS; Magalhães-Soares DF; Teixeira SM; Fernandes AP; Soto M; Tavares CA; Coelho EA
PLoS One; 2015; 10(9):e0137683. PubMed ID: 26367128
[TBL] [Abstract][Full Text] [Related]
36. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.
Rhee EG; Mendez S; Shah JA; Wu CY; Kirman JR; Turon TN; Davey DF; Davis H; Klinman DM; Coler RN; Sacks DL; Seder RA
J Exp Med; 2002 Jun; 195(12):1565-73. PubMed ID: 12070284
[TBL] [Abstract][Full Text] [Related]
37. Small Myristoylated Protein-3, Identified as a Potential Virulence Factor in Leishmania amazonensis, Proves to be a Protective Antigen against Visceral Leishmaniasis.
Oliveira MP; Martins VT; Santos TTO; Lage DP; Ramos FF; Salles BCS; Costa LE; Dias DS; Ribeiro PAF; Schneider MS; Machado-de-Ávila RA; Teixeira AL; Coelho EAF; Chávez-Fumagalli MA
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301342
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis.
Carrillo E; Crusat M; Nieto J; Chicharro C; Thomas Mdel C; Martínez E; Valladares B; Cañavate C; Requena JM; López MC; Alvar J; Moreno J
Vaccine; 2008 Mar; 26(15):1902-11. PubMed ID: 18321614
[TBL] [Abstract][Full Text] [Related]
39. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
40. Development of dominant epitope-based vaccines encoding Gp63, Kmp-11 and Amastin against visceral leishmaniasis.
Zhang J; He J; Liao X; Xiao Y; Liang C; Zhou Q; Chen H; Zheng Z; Qin H; Chen D; Chen Q; Li J; Chen J
Immunobiology; 2021 May; 226(3):152085. PubMed ID: 33910113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
